<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310335</url>
  </required_header>
  <id_info>
    <org_study_id>BEAH FTR-1</org_study_id>
    <nct_id>NCT01310335</nct_id>
  </id_info>
  <brief_title>Effect of Whole-Body Vibration on Plasma Sclerostin Level</brief_title>
  <acronym>WBV-SCL</acronym>
  <official_title>Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin&#xD;
      level in healthy young adult women.&#xD;
&#xD;
      Fifteen healthy young adult women are planned to include in this study. All cases will be&#xD;
      trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week&#xD;
      period. Training duration will be short at the beginning but progressed slowly.&#xD;
&#xD;
      The amplitude of vibration will be 2 mm and the frequency of the vibration will be 40 Hz. The&#xD;
      subjects will be asked to report negative side effects or adverse reactions in their training&#xD;
      diary.&#xD;
&#xD;
      Previbration and postvibration (just after, 10.minute and 30.minute) levels of plasma&#xD;
      sclerostin will be measured on first, second and fifth day of experiment. Sclerostin levels&#xD;
      will be measured by human sclerostin ELISA kit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whole-body vibration has a strong osteogenic effect. The cyclic mechanical loading to the&#xD;
      bone stimulates the osteocytes.&#xD;
&#xD;
      Sclerostin, the protein product of the SOST gene, is an osteocyte-specific cysteine&#xD;
      knot-secreted glycoprotein that is a potent inhibitor of bone formation. Sost/sclerostin&#xD;
      levels have been reported to be reduced by mechanical stimulation.&#xD;
&#xD;
      The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin&#xD;
      level in healthy young adult women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Sclerostin Level</measure>
    <time_frame>1 month</time_frame>
    <description>Change of plasma sclerostin level with whole-body vibration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The whole-body vibration (WBV) training</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>whole-body vibration (WBV)</intervention_name>
    <description>All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.</description>
    <arm_group_label>Training</arm_group_label>
    <other_name>Cyclic mechanical loading</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women,&#xD;
&#xD;
          -  Women with ages varying between 20 and 40 years&#xD;
&#xD;
          -  Right-handed women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lower extremity problems&#xD;
&#xD;
               1. Orthopedic problems: shortness of legs, congenital anomalies, etc.&#xD;
&#xD;
               2. Joint disease (arthritis, joint prosthesis, etc.)&#xD;
&#xD;
               3. Other painful pathologies in the lower extremities (fractures,&#xD;
                  tendinitis,bursitis, etc.)&#xD;
&#xD;
               4. Circulation problems in the lower extremities&#xD;
&#xD;
          -  Dorsolumbar diseases: Vertebral fract, disc hernias, spondylodiskitis, etc.&#xD;
&#xD;
          -  Systemic disease cases&#xD;
&#xD;
               1. Systemic bone disease: osteoporosis, osteomalacia, Paget's disease&#xD;
&#xD;
               2. Hypertension (&gt;135 mmHg systolic, &gt;85 mmHg diastolic)&#xD;
&#xD;
               3. Heart dis.(coronary dis, conduction/rhythm prob, cardiac pacemaker)&#xD;
&#xD;
               4. Infectious diseases&#xD;
&#xD;
               5. Endocrine diseases (Diabetes mellitus etc)&#xD;
&#xD;
          -  Neurological diseases (CNS problems, peripheral neuropathy)&#xD;
&#xD;
          -  Menstrual cycle disorders, amenorrhea, lactation, oral contraceptive use&#xD;
&#xD;
          -  Cases during the ovulatory period (11-16th day of menses)&#xD;
&#xD;
          -  Obesity (BMI &gt;30 kg/m2) or low BMI (BMI &lt;20 kg/m2)&#xD;
&#xD;
          -  Vertigo&#xD;
&#xD;
          -  Cognitive function disorders&#xD;
&#xD;
          -  Women whose blood samples were not taken in the time planned&#xD;
&#xD;
          -  Women whose blood samples hemolyzed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ILHAN KARACAN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training &amp; Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagcilar Training &amp; Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ilhan Karacan, Clinical Associated Professor</investigator_full_name>
    <investigator_title>Chief of Physical Med &amp; Rehab Clinic</investigator_title>
  </responsible_party>
  <keyword>sclerostin</keyword>
  <keyword>whole-body vibration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

